TuHURA Biosciences, Inc. (HURA)
NASDAQ: HURA · Real-Time Price · USD
2.560
+0.050 (1.99%)
May 14, 2026, 11:42 AM EDT - Market open
TuHURA Biosciences Employees
TuHURA Biosciences had 22 employees as of December 31, 2025. The number of employees increased by 3 or 15.79% compared to the previous year.
Employees
22
Change (1Y)
3
Growth (1Y)
15.79%
Revenue / Employee
n/a
Profits / Employee
-$1,366,379
Market Cap
162.76M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 22 | 3 | 15.79% |
| Dec 31, 2024 | 19 | 18 | 1,800.00% |
| Dec 31, 2023 | 1 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Protalix BioTherapeutics | 226 |
| Molecular Partners AG | 134 |
| Immunic | 92 |
| Connect Biopharma Holdings | 64 |
| Korro Bio | 49 |
| Spero Therapeutics | 25 |
| AN2 Therapeutics | 21 |
| Galectin Therapeutics | 9 |
HURA News
- 2 days ago - TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference - PRNewsWire
- 17 days ago - TuHURA Biosciences initiated with an Outperform at Citizens - TheFly
- 22 days ago - TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028 - PRNewsWire
- 4 weeks ago - TuHURA Biosciences initiated with a Buy at Rodman & Renshaw - TheFly
- 5 weeks ago - TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations - PRNewsWire
- 6 weeks ago - TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update - PRNewsWire
- 7 weeks ago - Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers - PRNewsWire
- 2 months ago - TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement - PRNewsWire